Table 2. Frequencies of analysed end points by the CBMN assay in peripheral blood mononuclear cells of BC cases and healthy controls.
|
Controls | All BC Cases | Pb | NMIBC | Pb | MIBC | Pb | |
---|---|---|---|---|---|---|---|---|
Frequenciesa | N | 148 | 152 | 136 | 16 | |||
MN | Mean±s.d. | 7.73±3.91 | 9.51±4.73 | 0.001 | 9.68±4.77 | 0.0005 | 8.06±4.24 | 0.91 |
NPB | Mean±s.d. | 0.88±0.90 | 0.98±1.03 | 0.61 | 0.99±1.03 | 0.55 | 0.88±1.09 | 0.85 |
NBUD | Mean±s.d. | 3.99±2.44 | 5.06±3.36 | 0.006 | 5.20±3.41 | 0.002 | 3.87±2.69 | 0.65 |
Abbreviations: BC=bladder cancer; MIBC=muscle-invasive bladder cancer; MN=micronuclei; NBUD=nuclear buds; NMIBC=non-muscle invasive bladder cancer; NPB=nucleoplasmic bridge.
Significant results in bold.
Mean frequencies for 1000 binucleated cells.
Wilcoxon Rank sum test.